Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

4 - Sientra, Inc. (0001551693) (Issuer)

4 - Sientra, Inc. (0001551693) (Issuer)

4 - Sientra, Inc. (0001551693) (Issuer)

8-K - Sientra, Inc. (0001551693) (Filer)

8-K - Sientra, Inc. (0001551693) (Filer)

8-K - Sientra, Inc. (0001551693) (Filer)

IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

SC 13G/A - Sientra, Inc. (0001551693) (Subject)

SC 13G - Sientra, Inc. (0001551693) (Subject)

SC 13G - Sientra, Inc. (0001551693) (Subject)